secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K/A
Filed at:   2026-10-01T21:29:23+00:00
Accession:  0001213900-26-105924
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.40
Item codes: 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Jasper 8-K/A details Kira merger financials: FY2025 net loss $4.4M, going-concern doubt, $132M preferred financing
--------------------------------------------------------------------------------

- Kira reported FY2025 net loss of $4.4M (vs $4.8M in FY2024); R&D expense fell to $0.9M from $2.8M and G&A was $1.5M.
- Auditor EisnerAmper cited substantial doubt about Kira's ability to continue as a going concern; accumulated deficit was $180.8M with only $0.6M cash at Dec 31, 2025.
- Concurrent private placement of non-voting convertible preferred stock raised $132.0M gross; Jasper must seek stockholder conversion vote within 120 days of the July 16, 2026 merger close.
- If conversion isn't approved in 12 months, holders can require Jasper to repurchase the preferred at fair value; the deal also includes contingent value rights and a Mirador License Agreement.
- Kira's Dec 31, 2025 balance sheet showed $1.1M total assets vs $8.9M liabilities, including $6.4M trade payables; a $3.95M loss on remeasurement of a related-party convertible note.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026105924/0001213900-26-105924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026105924/ea0306860-8ka1_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-105924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer